Evidence map›Paper›PMID 31560169›Full record

ArticleCancer medicine2019

Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection.

Hongmei Zheng, Yuting Zhan, Yuting Zhang, Sile Liu, Junmi Lu, Yang Yang, Qiuyuan Wen, Songqing Fan

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Pharmacological modulation of stress granulesFrontiers in pharmacology · 2026
    Review
  8. Article
  9. FBXW11 inhibits tumorigenesis by ubiquitinating YB1 in hepatocarcinoma.Journal of cancer research and clinical oncology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hongmei ZhengDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuting ZhanDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuting ZhangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Sile LiuDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Junmi LuDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yang YangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qiuyuan WenDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Songqing FanDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-1486-9909
Central South University · CN

Funding

National Natural Science Foundation of China 81472773National Natural Science Foundation of China 81703009National Natural Science Foundation of China 81773218Natural Science Foundation of Hunan Province 2017JJ3457
6 · The paper itself

Abstract

purposeG3BP1 is an RNA-binding protein and plays roles in regulating signaling pathway. YB-1 is a DNA/RNA binding protein encoded by YBX1 gene. Phosphorylated AKT (p-AKT) acts as a pivotal molecule in PI3K/AKT pathway. YB-1 drives stress granules (SGs) formation by activating G3BP1 translation under diverse conditions. SGs are involved in many different metabolic and signaling pathways which may include PI3K/AKT/mTOR. So far, there has been no report on the relationship between expression of G3BP1, p-AKT, and YB1 and clinicopathological features/prognosis in surgically resected nonsmall cell lung cancer (NSCLC) patients.

methodsIn this study, data from TCGA (The Cancer Genome Atlas) were downloaded to investigate the mRNA expression of G3BP1 and YB1 (YBX1) and their correlation in NSCLC. Also, expression of G3BP1, YB1, and p-AKT proteins was studied using immunohistochemistry in tissue microarrays of NSCLC and in noncancerous lung tissues.

resultsWe found that the mRNA expression of G3BP1 and YB1 was higher in NSCLC tissues (both P < .05), and G3BP1 was positively correlated with YB1 in mRNA level (r = .399, P < .001). Also, expression of G3BP1, YB1, and p-AKT proteins was higher in NSCLC tissues (all P < .05). And higher expression of G3BP1 and YB1 proteins was seen in patients with clinical stage II and III compared with stage I (both P < .05). Besides, expression of G3BP1 protein had a positive correlation with YB1 and p-AKT (both P < .05). Moreover, overall survival was shorter in patients with overexpression of G3BP1, YB1, and p-AKT proteins (all P < .05). Multivariate analysis confirmed that overexpression of G3BP1 protein was an independent poorer prognostic factor for NSCLC patients (P = .039).

conclusionG3BP1 may play a crucial role in activating PI3K/AKT/mTOR pathway. G3BP1 might be served as a novel prognostic biomarker for surgically resected NSCLC patients, which afforded new insights into the study on the mechanism and therapy of NSCLC.

Indexed as

BiomarkersCarcinoma, Non-Small-Cell LungDNA HelicasesFemaleHumansLungLung NeoplasmsMaleMiddle AgedPoly-ADP-Ribose Binding ProteinsPrognosisProto-Oncogene Proteins c-aktRNA HelicasesRNA Recognition Motif ProteinsY-Box-Binding Protein 1BiomarkersDNA HelicasesG3BP1 protein, humanPoly-ADP-Ribose Binding ProteinsProto-Oncogene Proteins c-aktRNA HelicasesRNA Recognition Motif ProteinsY-Box-Binding Protein 1YBX1 protein, humanbiomarkerG3BP1nonsmall cell lung cancerp-AKTprognosisYB1

Identifiers

PMID31560169
PMCPMC6853815
OpenAlexW2976575988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.